EGFR-IN-8|cas:2407957-87-1|西域试剂

EGFR-IN-8,98.31%

产品编号：Bellancom-126320| CAS NO：2407957-87-1| 分子式：C₃₂H₂₃ClF₃N₇O₄| 分子量：662.02

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-126320	￥3500.00	杭州北京（现货）
Bellancom-126320	￥5800.00	杭州北京（现货）
Bellancom-126320	￥16500.00	杭州北京（现货）
Bellancom-126320	￥25500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

EGFR-IN-8

产品介绍

EGFR-IN-8 是 EGFR 和 c-Met 双重抑制剂，化合物 48。EGFR-IN-8 有望成为进一步开发靶向 EGFR TKI 抗性 NSCLC 活性分子的靶点。

生物活性

EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.

体外研究

EGFR-IN-8 (0-20 μM; 24-72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97 cells at different time intervals, with IC₅₀ values ranging from 0.3 to 0.6 μM and 0.2-0.5 μM after 48 and 72 h of treatment respectively.
EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	A549, PC9, H1975, CL68, and CL97 cells
Concentration:	0-20 μM
Incubation Time:	24 hours, 48 hours, 72 hours
Result:	Showed inhibitory effects on different cells.

Western Blot Analysis

Cell Line:	A549, PC9, H1975, CL68, and CL97 cells
Concentration:	0-0.6 μM
Incubation Time:	48 hours
Result:	Decreased EGFR and c-Met expression.

体内研究
(In Vivo)

EGFR-IN-8 (oral gavage; 50 and 150 mg/kg; once daily; 20 days) exhibits a dose-dependent suppression (29% and 60%, respectively) of H1975 xenograft tumor growth at 50 and 150 mg/kg.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice H1975 xenograft tumor model
Dosage:	50 and 150 mg/kg
Administration:	Oral gavage; 50 and 150 mg/kg; once daily; 20 days
Result:	Inhibited H1975 xenograft tumor growth.

体内研究

EGFR-IN-8 (oral gavage; 50 and 150 mg/kg; once daily; 20 days) exhibits a dose-dependent suppression (29% and 60%, respectively) of H1975 xenograft tumor growth at 50 and 150 mg/kg.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice H1975 xenograft tumor model
Dosage:	50 and 150 mg/kg
Administration:	Oral gavage; 50 and 150 mg/kg; once daily; 20 days
Result:	Inhibited H1975 xenograft tumor growth.

体内研究

EGFR-IN-8 (oral gavage; 50 and 150 mg/kg; once daily; 20 days) exhibits a dose-dependent suppression (29% and 60%, respectively) of H1975 xenograft tumor growth at 50 and 150 mg/kg.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice H1975 xenograft tumor model
Dosage:	50 and 150 mg/kg
Administration:	Oral gavage; 50 and 150 mg/kg; once daily; 20 days
Result:	Inhibited H1975 xenograft tumor growth.

性状

Solid

溶解性数据

In Vitro:

DMSO : 8.33 mg/mL (12.58 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.5105 mL	7.5526 mL	15.1053 mL
5 mM	0.3021 mL	1.5105 mL	3.0211 mL
10 mM	0.1511 mL	0.7553 mL	1.5105 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式